London
· Delayed Price · Currency is GBP · Price in USD Imunon Company Description
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.
The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines.
Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
| Country | United States |
| Founded | 1982 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Stacy Lindborg |
Contact Details
Address: 997 Lenox Drive Lawrenceville, Delaware 08648 United States | |
| Phone | 609 896 9100 |
| Website | imunon.com |
Stock Details
| Ticker Symbol | 0HUZ |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US15117N6022 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael H. Tardugno | Executive Chairman, President and Chief Executive Officer |
| Jeffrey W. Church CPA, CPA | Chief Financial Officer, Executive Vice President and Corporate Secretary |
| Dr. Khursheed Anwer M.B.A., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Nicholas Borys | Executive Vice President and Chief Medical Officer |
| Timothy J. Tumminello | Chief Accounting Officer and Controller |
| Marianne M. Lambertson | Vice President of Communications and Investor Relations |